W.R. Grace has formally opened an expansion of the pharmaceutical CDMO expansion project it began 21 months ago at its site in South Haven, Michigan. The expansion has added 25% more capacity, including a new 15 m3 Hastelloy centrifuge and three 15 m3 multi-purpose chemical reactors.
Almac Group has announced the completion of two new purpose-built facilities at its headquarters in Craigavon, Northern Ireland. The total investment is about $400 million and is part of a global investment programme announced in June 2022.
One is a 2,600 m2 GMP facility that more than doubles peptide API manufacturing capacity. This “will enhance synthesis, purification and isolation capabilities and meet anticipated demand for clinical development and commercial products”, the company said.
Noramco, an API supplier specialised in controlled substances, has launched Noramco Group, which it describes as a “comprehensive North American-based supply chain solution” for clinical and commercial APIs and drug products. Noramco Group unites the capabilities of three subsidiaries:
* Delaware-based Noramco itself, which supplies APIs for both branded and generic drugs that are used in over 350 products
* Purisys, a Georgia-based supplier of CDMO services and pharmaceutical reference standards, with specialised capabilities in controlled substance APIs
CordenPharma has announced the commissioning of new GMP capacities at its Frankfurt site to manufacture early clinical phase peptide APIs. The investment is still being finalised, but will be fully operational in Q2 and authorised by German authorities in 2H.
Hovione has signed an agreement with Dragonfly Technologies to gain access to its micellar technology for chemistry-in-water processes, developed by Professor Bruce Lipshutz of the University of California, Santa Barbara. The company said that it will develop the technology to become an integral part of its API manufacturing technology offering.
During its full-year results presentation, CDMO and API supplier EuroAPI announced the launch of Focus-2027, a comprehensive project that will seek to unlock profitable growth and increase returns. Key means of achieving include:
* Streamlining the value-added API portfolio by discontinuing 13 with low or negative margins and focusing on highly differentiated, profitable products, such as vitamin B12, prostaglandins, peptides and oligonucleotides
* Having a focused CDMO offer “leveraging our recognised capabilities and technology platforms” *
Michael Levis of Siegfried overviews the possibilities of a key pharmaceutical technology
The pharmaceutical and biotechnology industries constantly seek innovative methods to enhance product stability, solubility, bioavailability and ease of use. Within this realm, CDMOs serve as invaluable partners in the development and production of high-quality drug products. Among the array of cutting-edge technologies that have transformed the CDMO industry, spray drying has emerged as a versatile and indispensable tool.
